These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20430458)

  • 21. The role of local excision in rectal cancer after complete response to neoadjuvant treatment.
    Coco C; Manno A; Mattana C; Verbo A; Rizzo G; Valentini V; Gambacorta MA; Vecchio FM; D'Ugo D
    Surg Oncol; 2007 Dec; 16 Suppl 1():S101-4. PubMed ID: 18023178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer.
    Yeo SG; Kim DY; Kim TH; Jung KH; Hong YS; Chang HJ; Park JW; Lim SB; Choi HS; Jeong SY
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):164-71. PubMed ID: 20004532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
    Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study.
    Gambacorta MA; Valentini V; Morganti AG; Mantini G; Miccichè F; Ratto C; Di Miceli D; Rotondi F; Alfieri S; Doglietto GB; Vargas JG; De Paoli A; Rossi C; Cellini N
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):130-8. PubMed ID: 15337548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
    Ratto C; Ricci R; Valentini V; Castri F; Parello A; Gambacorta MA; Cellini N; Vecchio FM; Doglietto GB
    Ann Surg Oncol; 2007 Feb; 14(2):853-61. PubMed ID: 17103068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
    Ratto C; Ricci R; Valentini V; Castri F; Parello A; Gambacorta MA; Cellini N; Vecchio FM; Doglietto GB
    Ann Surg Oncol; 2006 Nov; 13(11):1393-402. PubMed ID: 17013687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy.
    Kojima M; Ishii G; Yamane Y; Nishizawa Y; Saito N; Ochiai A
    Pathol Int; 2009 Dec; 59(12):857-62. PubMed ID: 20021610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Carlomagno C; Pepe S; D'Armiento FP; D'Armiento M; Cannella L; De Stefano A; Crispo A; Giordano M; De Placido S
    Oncology; 2010; 78(5-6):369-75. PubMed ID: 20798559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor regression in mesorectal lymphnodes after neoadjuvant chemoradiation for rectal cancer.
    Caricato M; Ausania F; De Dominicis E; Vincenzi B; Rabitti C; Tonini G; Cellini F; Coppola R
    Eur J Surg Oncol; 2007 Aug; 33(6):724-8. PubMed ID: 17336482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
    Díaz-González JA; Calvo FA; Cortés J; García-Sabrido JL; Gómez-Espí M; Del Valle E; Muñoz-Jiménez F; Alvarez E
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1122-8. PubMed ID: 16406393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of tumor regression grade on long-term survival in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Sakin A; Sahin S; Sengul Samanci N; Yasar N; Demir C; Geredeli C; Erhan SS; Akboru MH; Cihan S
    J Oncol Pharm Pract; 2020 Oct; 26(7):1611-1620. PubMed ID: 32046577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy.
    Huh JW; Kim HC; Kim SH; Park YA; Cho YB; Yun SH; Lee WY; Park HC; Choi DH; Park JO; Park YS; Chun HK
    Surgery; 2019 Mar; 165(3):579-585. PubMed ID: 30314723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
    Kim YS; Kim JH; Yoon SM; Choi EK; Ahn SD; Lee SW; Kim JC; Yu CS; Kim HC; Kim TW; Chang HM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):796-802. PubMed ID: 19289261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Ryan R; Gibbons D; Hyland JM; Treanor D; White A; Mulcahy HE; O'Donoghue DP; Moriarty M; Fennelly D; Sheahan K
    Histopathology; 2005 Aug; 47(2):141-6. PubMed ID: 16045774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of intraoperative presacral electron boost radiotherapy (IOERT) in combination with total mesorectal excision (TME) and chemoradiation in patients with locally advanced rectal cancer.
    Krempien R; Roeder F; Oertel S; Roebel M; Weitz J; Hensley FW; Timke C; Funk A; Bischof M; Zabel-Du Bois A; Niethammer AG; Eble MJ; Buchler MW; Treiber M; Debus J
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1143-51. PubMed ID: 16979835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.
    Glynne-Jones R; Mawdsley S; Novell JR
    Colorectal Dis; 2006 Nov; 8(9):800-7. PubMed ID: 17032329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.
    Moore HG; Shia J; Klimstra DS; Ruo L; Mazumdar M; Schwartz GK; Minsky BD; Saltz L; Guillem JG
    Ann Surg Oncol; 2004 Nov; 11(11):955-61. PubMed ID: 15525823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.